Yiyang Huoluo Decoction

Phase 2Small molecule

XXia Liang

Yiyang Huoluo Decoction is one of 44 small molecule programs targeting Heart Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart DiseaseRecruiting

Heart DiseasePhase 2

Recruiting

Competition

Competitive Landscape

56 competitors in Heart Disease

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Approved

3 2

Bayer Aspirin

Bayer

Approved

2 3

Colcrys

Jazz Pharmaceuticals

Approved

2 4

Corlanor

Amgen

Approved

1 5

Lorelco

Sanofi

Approved

1 6

Leqvio

Novartis

Approved

1 7

Savaysa

Pletal

1 9

Nexium

DDexcel Pharma Technologies Ltd.

Approved

1 10

Heparin Sodium

BBaxter Healthcare Corporation

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1/2Recruiting

Heart Disease

NCT07493603

Clinical

Trials by Indication[1]

Heart Disease1 trial

A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease

Recruiting·XXia Liang·Phase 1/2·NCT07493603·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Yiyang Huoluo Decoction. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Yiyang Huoluo Decoction compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Yiyang Huoluo Decoction. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xia Liang company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: XXia Liang

Yiyang Huoluo Decoction

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Heart Disease1 trial

References

Drug Info

Quick Facts

Related News